Powder: -20°C for 3 years | In solvent: -80°C for 1 year
USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. USL311 inhibits CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells, with anti-tumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 83.00 | |
2 mg | In stock | $ 118.00 | |
5 mg | In stock | $ 198.00 | |
10 mg | In stock | $ 288.00 | |
25 mg | In stock | $ 482.00 | |
50 mg | In stock | $ 697.00 | |
100 mg | In stock | $ 992.00 | |
500 mg | In stock | $ 1,980.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 228.00 |
Description | USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. USL311 inhibits CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells, with anti-tumor activity. |
Molecular Weight | 422.57 |
Formula | C24H34N6O |
CAS No. | 1373268-67-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 24 mg/mL (59.79 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
USL311 1373268-67-7 Autophagy GPCR/G Protein Immunology/Inflammation CXCR anti-tumor USL 311 CXC chemokine receptors glioma inhibit USL-311 Inhibitor inhibitor